Utreloxastat

Utreloxastat (PTC857) is an orally active and blood-brain barrier-permeable 15-lipooxygenase inhibitor. Utreloxastat is a weak inhibitor of CYP1A2 and 2B6 with an IC50 of >5.3 μM. Utreloxastat reduces oxidative stress and inhibits the consumption of reduced glutathione and ferroptosis. Utreloxastat can be used in the study of neurodegenerative diseases characterized by high levels of oxidative stress and mitochondrial pathology, such as amyotrophic lateral sclerosisc[1][2].

Product Specifications

CAS Number

[1213269-96-5]

Product Name Alternative

PTC857

UNSPSC

12352211

Target

Cytochrome P450; Ferroptosis; Lipoxygenase; α-synuclein

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/utreloxastat.html

Purity

99.69

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C(C)=C(C)C(C(C)=C1CCCCCCCCC)=O

Molecular Formula

C18H28O2

Molecular Weight

276.41

References & Citations

[1]Andrew W. Hinman, et al. 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS. WO2020081879A2.|[2]Gao L, et al. First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis. Clin Pharmacol Drug Dev. 2023 Feb;12 (2) :141-151.